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Internal ribosome entry site (IRES)-mediated translation of input viral RNA is the initial required
step for the replication of the positive-stranded genome of hepatitis C virus (HCV). We have
shown previously the importance of the GCAC sequence near the initiator AUG within the stem
and loop IV (SLIV) region in mediating ribosome assembly on HCV RNA. Here, we demonstrate
selective inhibition of HCV-IRES-mediated translation using short hairpin (sh)RNA targeting the
same site within the HCV IRES. sh-SLIV showed significant inhibition of viral RNA replication in a
human hepatocellular carcinoma (Huh7) cell line harbouring a HCV monocistronic replicon. More
importantly, co-transfection of infectious HCV–H77s RNA and sh-SLIV in Huh7.5 cells
successfully demonstrated a significant decrease in viral RNA in HCV cell culture. Additionally, we
report, for the first time, the targeted delivery of sh-SLIV RNA into mice liver using Sendai
virosomes and demonstrate selective inhibition of HCV-IRES-mediated translation. Results
provide the proof of concept that Sendai virosomes could be used for the efficient delivery of
shRNAs into liver tissue to block HCV replication.
INTRODUCTION
Hepatitis C virus (HCV) has infected over 180 million
people and the majority of them are at risk of developing
liver cirrhosis and/or hepatocellular carcinoma (Saito et al.,
1990). The current treatment regimen available for HCV
infection includes pegylated-interferon-a in combination
with ribavirin, which has limitations in its efficacy, as many
patients don’t respond to this therapy (Iwasaki et al., 2006),
and also results in unwanted side effects. There is therefore
an urgent need to develop an effective and specific antiviral
for combating HCV disease progression. Several approaches
targeting different regions of the viral genome are being
investigated, such as serine–protease inhibitors, monoclonal
antibodies, anti-fibrotics, immunosuppressants and immu-
nomodulators (Pawlotsky et al., 2007; Tan et al., 2002).
There are initiatives to develop nucleic acid-based antiviral
agents, such as short hairpin (sh)RNA, short interfering
(si)RNA, ribozymes and DNAzymes targeting non-coding
regions, structural and non-structural proteins, which have
shown moderate or better inhibition at the level of protein
synthesis and replication (Trepanier et al., 2006).
The synthesis of HCV proteins is mediated by the 59 cap-
independent internal initiation mechanism, where the
loading of the ribosome onto HCV RNA is mediated
through a highly structured RNA element, the internal
ribosome entry site (IRES) (Wang et al., 1993). Since the
mechanism of ribosome assembly is unique and fun-
damentally different from the cap-dependent translation of
the host cell mRNA, it can be targeted to selectively inhibit
viral protein synthesis and consequently its replication
(Dasgupta et al., 2004; Hellen & Sarnow, 2001; Trowbridge
& Gowans, 1998). Previously, we have demonstrated the
importance of the GCAC sequence near the iAUG for
ribosome assembly onto HCV IRES RNA (Pudi et al., 2003,
2005). In fact, human La protein (an important host
factor) has been shown to bind to the above sites and a
peptide derived from the RNA-binding region of La
protein has been shown to interfere with the ribosome
assembly and inhibit viral RNA translation (Ali et al., 2000;
Mondal et al., 2008; Pudi et al., 2004, 2005). Here, we have
investigated the ability of an shRNA targeting this region of
HCV IRES to inhibit translation and replication of viral
RNA.
Several approaches have been reported to inhibit HCV
RNA translation or replication targeting different regions
of the viral RNA, using either small RNA decoy, DNA or
RNA aptamers, siRNAs or shRNAs, ribozymes, DNAzymes,
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peptides etc. (Dasgupta et al., 2004; Pawlotsky et al., 2007;
Roy et al., 2008). However, to date, a suitable system for
selective and efficient delivery of small nucleic acid
molecules into liver cells is lacking. F-virosomes derived
from Sendai virus have been shown to be capable of
liver-specific membrane-fusion-mediated delivery of
drugs/genes to hepatocytes. It has been well established
that these virosomes are selectively targeted to the
hepatocytes of mice both in vitro and in vivo (Bagai et
al., 1993; Nijhara et al., 2001; Ramani et al., 1998). Thus,
in this study we have exploited the F-virosomal delivery
of shRNA for its targeted expression and report for the
first time the targeted delivery of HCV-specific shRNA
into mouse liver as a proof of concept to demonstrate
significant inhibition of HCV IRES-mediated translation
in vivo using mice.
METHODS
Plasmid constructs. A relatively conserved and unique sequence
within HCV IRES was selected to construct shRNA lacking homology
with cellular genes. shRNA oligonucleotides were designed to contain
a sense strand of 19 nt, followed by a short spacer (TTCAAGAGA),
the reverse complement of the sense strand and five thymidines as a
stop signal. sh-Stem and loop IV (SLIV) was designed by targeting the
HCV IRES corresponding to nt 331–350. Additionally, to generate a
non-specific control shRNA (Nsp-sh) a non-specific sequence was
also cloned in the poly-linker region of the pSUPER vector. The target
sequence of sh-SLIV is 59-GACCGUGCACCAUGAGCAC-39 and of
Nsp-shRNA is 59-CAGUCGCGUUUGCGACUGG-39. To clone the
shRNA-encoding DNA sequences, sense and antisense strand
oligonucleotides corresponding to the target sequences were dena-
tured at 95 uC and annealed by gradually cooling to 4 uC; these were
then cloned into the BglII and HindIII sites of pSUPER vector
(Brummelkamp et al., 2002). The bicistronic plasmid construct
(RLuc–HCV-IRES–FLuc) containing HCV IRES in between renilla
luciferase (Rluc) and firefly luciferase (Fluc) genes was cloned into the
pCDNA3.1 vector. In this bicistronic construct, the Rluc reporter
gene represents the cap-dependent translation, whereas Fluc trans-
lation is mediated by the HCV IRES (Pudi et al., 2003). Similarly, the
Coxsackievirus B3 (CVB3) bicistronic construct, which contains the
CVB3 IRES between Rluc and Fluc (Bhattacharyya et al., 2008), was
used as a non-specific IRES control. pSV-b-gal plasmid (Promega)
was used as a control reporter plasmid for normalizing transfection
efficiency. pSUPER vector alone (without shRNA) was used as a
control.
Cell cultures.Human hepatocellular carcinoma (Huh) 7 and Huh7.5
cell monolayers were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) at 37 uC in 5% CO2. To cells harbouring the
HCV monocistronic replicon (a kind gift from Dr Ralf
Bartenschlager, Heidelberg University, Germany), 25 mg hygromycin
B ml21 was added to the culture medium (Frese et al., 2003).
Transient co-transfection of shRNA.Monolayers (70% confluent)
of Huh7 cells in 35 mm dishes were co-transfected with the shRNA
plasmid construct and the HCV bicistronic plasmid DNAs or the
CVB3 bicistronic construct along with a b-galactosidase (b-gal)
construct using Tfx20 transfection reagent (Promega). Cells were
harvested 24 h post-infection using passive lysis buffer (Promega) and
Fluc and Rluc activities were measured using the Dual Luciferase
assay system (Promega) in a TD 20/20 Luminometer (Turner
Designs); the activities were normalized with respect to b-gal
expression of the cells.
A cell culture-adapted infectious H77s–cDNA construct (a generous
gift from Stanley Lemon, University of Texas, Galveston, USA) was
used to generate H77s RNA after linearization with XbaI followed by
run-off transcription. The respective shRNA constructs (0.5 mM) and
the infectious H77s RNA (0.4 mM) were co-transfected into Huh7.5
cells using Lipofectamine 2000 (Invitrogen). Total cellular RNA was
extracted 72 h post-transfection (p.t.) and quantitative RT-PCR
(qRT-PCR) was performed.
shRNA transfection in Huh7 cells harbouring the HCV replicon.
Transfection of shDNA constructs into cells harbouring HCV
replicons was performed as described previously (Roy et al., 2008).
Briefly, Huh7 cells harbouring the monocistronic HCV (genotype 2a)
replicon, were transfected with either pSUPER vector (a generous gift
from Dr Rene Bernards, Netherlands) alone (as control) or with
0.5 mM of the plasmid constructs encoding sh-SLIV or Nsp-sh RNA.
Total RNA was isolated 48 h p.t. using Tri Reagent (Sigma) and RT-
PCR was carried out as stated below. For the colony formation assay,
cells were trypsinized 24 h p.t. and 46103 cells were seeded in 35 mm
dishes, incubated for 10 days in the presence of 25 mg hygromycin B
ml21. The cells were fixed with 90% acetone, stained with Brilliant
Blue G-250 in 40% methanol and 10% acetic acid; colonies were
counted and the approximate percentage c.f.u. was calculated
compared with the control.
Semiquantitative RT-PCR analysis. Semiquantitative RT-PCR was
performed for HCV IRES positive and negative strand RNAs using
standard protocols, as described previously (Roy et al., 2008). The
PCR products were analysed on 1.2% agarose gels. cDNA synthesis
from the positive and negative strands was performed using strand-
specific primers. GAPDH was also amplified using the relevant primer
as an internal control in the same reaction. Quantification of the
replicon RNA was performed by real-time PCR analysis of the
respective cDNAs synthesized using the qRT-PCR SYBR green kit
(Finnzymes) following the manufacturer’s protocol, using an Applied
Biosystems 7900HT machine.
Sendai virus culture and preparation of plasmid DNA-loaded F-
virosomes. Sendai virus (Z strain) was grown in 10–11-day-old
embryonated chicken eggs, harvested and purified by following
published protocols (Bagai et al., 1993). Viral yield was estimated in
terms of protein and its fusogenic activity was checked. Reconstituted
Sendai viral envelopes containing the F-protein (F-virosomes) were
prepared as described by Bagai et al. (1993) and Ramani et al. (1998).
Briefly, 100 mg Sendai virus envelope was reduced with 3 mM DTT
at 37 uC followed by dialysis to remove haemagglutinin neuramini-
dase (HN) protein. The suspension was finally resuspended in non-
ionic detergent for 1 h; this resulted in removal of HN as well as the
viral genetic material containing the RNA genome. The supernatant
from the detergent extract was mixed with the desired plasmid DNA
(HCV bicistronic DNA construct with or without shRNA constructs)
and reconstituted by stepwise removal of detergent using SM-2
Biobeads (Bio-Rad). The final virosome pellet was suspended in
10 mM PBS.
Fusion-mediated delivery of plasmids to cell lines. Monolayers
of Huh7 cells (in 12-well culture plates; Falcon) were washed twice
with 1 ml DMEM without serum. Cells were incubated with loaded
F-virosomes (0.3 mg F-protein) containing 3–4 mg HCV bicistronic
plasmid construct with or without sh-SLIV or Nsp-sh plasmid at
37 uC at 5% CO2 in 2 ml serum-free medium. Cells alone were used
as controls. After 2 h of fusion, medium was replaced with DMEM
containing 10% FBS and cells were further incubated for 24 h at
shRNA targeting HCV RNA
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37 uC at 5% CO2. The luciferase reporter assay was performed as
stated above.
Administration of loaded virosomes to BALB/c mice. Twelve-
week-old male BALB/c mice were maintained under specific
pathogen-free conditions in the animal facility. These BALB/c mice
(~20 g) were given two injections (at an interval of 24 h)
intravenously into the tail vein. The injection consisted of HCV
bicistronic plasmid with or without sh-SLIV or Nsp-sh plasmid-
loaded F-virosomes (containing 4 mg DNA) in a final volume of
0.2 ml Tris-buffered saline containing 2 mM Ca2+. The equivalent
volume of PBS was injected as a control (with or without the same
amount of free DNA). Two days post-injection, animals were
sacrificed for hepatocyte isolation.
Isolation and gene expression in isolated hepatocytes. Liver
parenchymal cells were isolated by collagenase perfusion of the liver
following a standard procedure (Nijhara et al., 2001). Briefly, the
perfused liver was excised from the animal, cut into small pieces and
washed thoroughly with phosphate buffer, pH 7.4. The liver pieces
were incubated at 37 uC for 30 min in a buffer containing collagenase
A (hepatocyte qualified; Gibco). The resulting liver mass was filtered
through a nylon mesh and the filtrate was centrifuged at 500 g for
10 min at 4 uC to obtain a pellet containing the hepatocytes. The
non-hepatocyte pellet was obtained by centrifuging the supernatant at
1500 g for 10 min at 4 uC. Both of these cell types were washed three
times with ice-cold PBS, pH 7.4, lysed with passive lysis buffer
(Promega) and the cell extracts were then subjected to a dual
luciferase assay.
Statistical analysis. All statistical analyses were performed using
Student’s t-test. All graphs represent mean±SD. P-values were
determined by using a paired t-test. P-values of less than 0.01 were
considered to be statistically significant.
RESULTS
Inhibition of HCV RNA translation by shRNA
targeting the IRES element
Specific shRNA targeting SLIV (encompassing the GCAC
and the iAUG sequence) of the HCV IRES (Fig. 1) has been
designed and cloned into pSUPER vector (Brummelkamp
et al., 2002) to generate sh-SLIV. A non-specific sequence
was also cloned in the poly-linker region of the pSUPER
vector to generate Nsp-sh.
Fig. 1. Targeting the SLIV region of HCV IRES using shRNA.
(a) Schematic representation of stem–loop III and SLIV of the HCV
IRES (adapted fromBrown et al., 1992). The target site within SLIV is
indicated by grey shading and the GCAC sequence is boxed. (b) A
range of concentrations of sh-SLIV construct were co-transfected
with 0.25 mM HCV bicistronic contruct and pSV40 b-gal plasmid
DNA to normalize transfection efficiency. Cells were harvested 24 h
p.t. and luciferase activities were measured. The luciferase activities
were normalized with protein concentration of the lysates and the b-
gal activity for the transfection efficiency. *Values that significantly
differ from controls (P,0.001).
Fig. 2. sh-SLIV RNA specifically inhibits HCV-IRES-mediated
translation in Huh7 cells. Bicistronic DNA constructs containing
HCV (a) or CVB3 (b) IRESs were co-transfeted with shRNA
constructs and b-gal. Luciferase activity was measured and normal-
ized with b-gal (Control, taken as 100%). Data shown are the
mean±SD of three independent experiments carried out in duplicate.
*Values which significantly differ from controls (P,0.001).
N. Subramanian and others
1814 Journal of General Virology 90
A range of concentrations of the sh-SLIV construct were
co-transfected with the HCV bicistronic contruct (RLuc–
HCV-IRES–FLuc) and pSV40 b-gal plasmid DNA and the
luciferase activity was measured in cells harvested 24 h p.t.
The luciferase activities were normalized to the protein
concentration of the lysates and the b-gal activity for the
transfection efficiency (Fig. 1b).
Our results showed that there was significant inhibition of
HCV-IRES-mediated translation upon transfection of
Huh7 cells with sh-SLIV (Fig. 2a). However, Nsp-sh did
not significantly inhibit HCV-IRES-mediated translation.
To further demonstrate the specificity of sh-SLIV function,
a similar experiment was performed using the bicistronic
construct containing the IRES element of CVB3. These
data showed that there was no significant inhibition of
CVB3 translation by HCV-specific shRNA (Fig. 2b),
reconfirming the target specificity of the sh-SLIV for the
HCV IRES RNA.
Effect of sh-SLIV RNA on HCV replication in
replicon cell line and in HCV cell culture
To investigate the effect of the sh-SLIV on HCV RNA
replication, sh-SLIV, Nsp-sh or pSuper vector control
DNA was transfected into Huh7 cells harbouring the HCV-
monocistronic replicon, maintained with hygromycin B
(Frese et al., 2003) (Fig. 3a). Total cellular RNA was
isolated 48 h p.t. Semiquantitative RT-PCR analysis of
RNA iolated 48 h p.t. indicated that there was considerable
inhibition of both positive- and negative-strand synthesis
(Fig. 3b). To reconfirm these data, the replicon RNA was
quantified by real-time PCR analysis. The results showed
Fig. 3. Effect of shRNA ex vivo in Huh7 cells harbouring the HCV monocistronic replicon. (a) Schematic representation of the
HCV monocistronic replicon (adapted from Frese et al., 2003). (b) Either pSUPER vector alone (Control) or plasmid constructs
encoding sh-SLIV or Nsp-sh were transfected in Huh7 cells harbouring the HCV monocistronic replicon. RNA [positive (+) and
negative (”)] isolated 48 h p.t. was analysed by semiquantitative RT-PCR. (c) The RNA was also analysed by qRT-PCR. The
HCV RNA levels for positive and negative strand RNA were calculated after normalizing with GAPDH. (d) Cells infected as in (a)
were trypsinized, seeded into 35 mm dishes and incubated with hygromycin B for 10 days. Cells were fixed with 90% acetone
and stained with Brilliant Blue G-250 to calculate the c.f.u. Percentage values represent the curing of Huh7 cells from HCV
replicon RNA in the presence of sh-SLIV (97%) and Nsp-sh (3%).
shRNA targeting HCV RNA
http://vir.sgmjournals.org 1815
significant inhibition of both positive (2.25-fold decrease,
80% inhibition) and negative (3.1-fold decrease, 90%
inhibition) strands when transfected with the sh-SLIV
construct. In contrast, the Nsp-shRNA showed only
marginal inhibition (Fig. 3c).
As the inhibition was between 80 and 90%, we intended to
determine whether the shRNAs completely eliminate viral
RNA in a given cell. The efficacy of shRNA for curing of
replicating HCV RNA in Huh7 cells at the single cell level
was assessed by colony formation assay. This showed that
around 97% of cells were virus free or survived in the
presence of sh-SLIV compared with the control or Nsp-
shRNA (~3%) (Fig. 3d).
To evaluate the efficacy of sh-SLIV RNA to inhibit HCV
replication in cell culture, HCV-H77s RNA was generated
from a cell culture-adapted infectious H77s–cDNA construct
(Fig. 4a) (Yi et al., 2006). Co-transfection of shRNA
constructs and infectious H77s RNA resulted in a consid-
erable inhibition of both the strands of HCV RNA. The
positive strand was inhibited by 3.4-fold (93%) and the
negative strand was inhibited by 2.7-fold (80%). However,
the Nsp-sh or pSUPER vector did not show notable
inhibition of either strand (Fig. 4b).
Effect of virosome-loaded sh-SLIV RNA ex vivo in
Huh7 cells and in vivo in BALB/c mice
To explore a suitable delivery system for the shRNA
constructs, we opted to use Sendai virosomes, which are
popular for selective and effective delivery into liver cells
(Ramani et al., 1998). Fig. 5(a) represents the process used
for preparation of virosomes loaded with shRNA construct.
The engineered virosome and the delivery strategy in
BALB/c mice are shown in Supplementary Fig. S1
(available in JGV Online). Essentially, the engineered
Sendai virosomes (suitable for the delivery of the
shRNAs) were packed with HCV bicistronic DNA
construct with or without shRNA construct and used for
transfection into Huh7 cells and BALB/c mice. In order to
achieve a systematic assessment of the ability of F-
virosome-mediated delivery of this shRNA and its ability
to inhibit HCV IRES in a liver-derived cell line, monolayers
of Huh7 cells were transfected with virosomes loaded with
HCV bicistronic construct and sh-SLIV or Nsp-sh
construct. Luciferase activity was measured 24 h p.t.
Significant inhibition (~80%) of HCV-IRES-mediated
translation was observed in the presence of the sh-SLIV
compared with the control. However, Nsp-sh showed very
little or negligible inhibition of HCV-IRES-mediated
translation (Fig. 5b). The results suggest that there is
efficient delivery of the virosome-entrapped shRNA
constructs inside liver-derived Huh7 cells and selective
inhibition of HCV-IRES-mediated translation. We have
also tried the experiment of separate trapping of HCV-
bicistronic DNA and the sh-SLIV construct in the
virosomes; subsequent delivery to Huh7 cells showed only
16–20% inhibition (Supplementary Fig. S2, available in
JGV Online).
To investigate whether the Sendai virosomes packed with
reporter gene constructs could deliver the DNAs selectively
into liver cells in the context of the whole animal (BALB/c
mouse), we first tested the preferential expression of
Fig. 4. Effect of shRNA ex vivo on the replication of HCV–H77s RNA in cell culture. (a) Schematic representation of the HCV–
H77s construct (adapted from Yi et al., 2006). (b) In vitro-transcribed HCV RNA from the HCV–H77s construct was transiently
co-transfected with either pSUPER vector alone (Control) or sh-SLIV or Nsp-sh plasmid constructs in Huh7.5 cells. RNA was
extracted 72 h p.t. and qRT-PCR analysis was performed. The percentage HCV RNA levels (mean±SD) were calculated for the
positive and negative strand after normalizing with GAPDH (Control).
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luciferase gene loaded into Sendai F-virosome by intra-
venous (i.v.) injection through the tail vein. It was observed
that the expression of the luciferase reporter gene occurred
preferentially in the parenchymal cells (hepatocytes) of the
mouse liver, compared with Kupffer cells (non-hepatocyte
cells) (Fig. 6a), which is consistent with an earlier
publication (Ramani et al., 1998). To assess the target
specificity of F-virosomes to deliver sh-SLIV and inhibit
HCV-IRES-mediated translation in vivo, F-virosomes
containing HCV bicistronic construct and sh-SLIV or
Nsp-sh encoding plasmids were delivered to BALB/c mice
by using multiple i.v. injections through the tail vein. Livers
from injected animals were analysed for luciferase activity.
Mice treated with the sh-SLIV construct showed a
significant reduction (75%) in HCV-IRES-mediated trans-
lation of Fluc, compared with that in the control animal
that received virosomes containing HCV bicistronic
construct alone (Fig. 6b). Free plasmid/buffer-injected
animals showed no inhibition and served as an additional
negative control (data not shown).
DISCUSSION
So far, several shRNAs targeting different regions of the
HCV genome have been reported to achieve significant
inhibition of translation and replication of viral RNA
(Kanda et al., 2007; Kapadia et al., 2003; Randall et al.,
2003; Wilson et al., 2003). Some of the target sequences
used were shown to be conserved across the genotypes.
However, the scope of an siRNA-/shRNA-based antiviral
strategy in general is limited because of the evolution of
escape mutants. In this study, we purposely targeted the
site (nt 331–350) within the SLIV region which encom-
passes cis-acting elements critical for ribosome assembly
and which is likely to be more conserved in the HCV RNA
Fig. 5. Entrapment of shRNA-encoding plasmid constructs in the Sendai virosome. (a) Schematic representation of Sendai
F-virosome preparation (following the protocol of Ramani et al., 1998). (b) Dual luciferase activity of Huh7 cells harvested 24 h
post-fusion of F-virosome with either sh-SLIV or Nsp-sh constructs. Data shown are mean±SD, taking the control as 100%.
*Values which significantly differ from controls (P,0.001).
shRNA targeting HCV RNA
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and is protected from the generation of escape variants
(Pudi et al., 2004). Thus, the sh-SLIV could be used to
achieve broad spectrum inhibition of HCV translation and
replication.
Presumably, the sh-SLIV RNA inhibits HCV-IRES-mediated
translation by cleaving the bicistronic RNA, as its sequence is
exactly complementary to the target sequence. However, we
do not rule out the possibility of any off-target activity by
which shRNA might interfere with cellular factors critical for
IRES function or induce double-stranded RNA-activated
protein kinase, which in turn would contribute to inhibition
of translation. sh-SLIV showed almost 80% translation
inhibition and up to 90% replication inhibition of the
replicon system and H77S RNA [full-length HCV genome
that replicates and produces virus particles that are infectious
in cell culture (HCVcc)] in an HCV cell culture assay,
suggesting that sh-SLIV could be effective in inhibiting viral
proliferation. Additionally, it would be interesting to use a
cocktail of shRNAs (packed in a Sendai virosome) targeting
different regions of the HCV genome to further potentiate
the inhibitory activity.
Furthermore, in this study we have demonstrated target-
specific silencing of the HCV RNA using Sendai virus F-
virosomes, which are widely used for their liver specificity
and efficient targeted delivery compared with cationic
liposomes (Ramani et al., 1998). Although several methods
have been tried for the delivery of siRNA/shRNA
molecules, which includes adenoviral and retroviral
delivery systems (Kronke et al., 2004; Zhang et al., 2004),
none of these are selective for hepatocytes. Studies using
mice as the animal model utilize tail vein injection or
hydrodynamic injection for delivery of shRNAs, which
requires a high dose as it is distributed systemically (Wang
et al., 2005). Therefore, the present delivery mode using
Sendai virosomes can ensure targeted delivery into the
mouse liver and could minimize the effective dose.
Finally, this study provides, for the first time, proof of
concept for the targeted delivery of anti-HCV molecules
into mouse liver cells using Sendai virosome, which could
be a novel and effective delivery strategy to block HCV
proliferation in liver tissue.
ACKNOWLEDGEMENTS
We thank Drs A. Nomoto, R. Bartenschlager, V. Lohmann, R.
Bernards and S. Lemon for providing us with plasmid constructs and
useful reagents. We also thank Dr Krishna K. Murthy for his valuable
suggestions. We gratefully acknowledge our lab members for their
help and discussion. This work was supported by a grant from the
Department of Biotechnology, Government of India, to S. D. and
D. P. S. Special financial support to D. P. S. from the University of
Delhi is acknowledged.
REFERENCES
Ali, N., Pruijn, G. J. M., Kenan, D. J., Keene, J. D. & Siddiqui, A. (2000).
Human La antigen is required for the hepatitis C virus internal
ribosome entry site (IRES)-mediated translation. J Biol Chem 275,
27531–27540.
Bagai, S., Puri, A., Blumenthal, R. & Sarkar, D. P. (1993).
Hemagglutinin-neuraminidase enhances F protein-mediated mem-
brane fusion of reconstituted Sendai virus envelopes with cells.
J Virol 67, 3312–3318.
Bhattacharyya, S., Verma, B., Pandey, G. & Das, S. (2008). The
structure and function of a cis-acting element located upstream of the
IRES that influences Coxsackievirus B3 RNA translation. Virology
377, 345–354.
Brown, E. A., Zhang, H., Ping, L. H. & Lemon, S. M. (1992). Secondary
structure of the 59 nontranslated regions of hepatitis C virus and
pestivirus. Nucleic Acids Res 20, 5041–5045.
Brummelkamp, T. R., Bernards, R. & Agami, R. (2002). A system for
stable expression of short interfering RNAs in mammalian cells.
Science 296, 550–553.
Dasgupta, A., Das, S., Izumi, R., Venkatesan, A. & Barat, B. (2004).
Targeting internal ribosome entry site (IRES)-mediated translation to
block hepatitis C and other RNA viruses. FEMS Microbiol Lett 234,
189–199.
Fig. 6. Inhibition of HCV-IRES-mediated translation in vivo in
BALB/c mice by shRNA delivered through F-Virosomes. (a)
Preferential expression of HCV bicistronic construct in the liver
cells following intravenous injection by F-virosomes. (b) Relative
luciferase activities (mean±SD) of liver parenchymal cells from
BALB/c mice injected i.v. with F-virosomes loaded with the HCV
bicistronic constructs and either sh-SLIV or Nsp-sh. *Values which
significantly differ from controls (P,0.001).
N. Subramanian and others
1818 Journal of General Virology 90
Frese, M., Barth, K., Kaul, A., Lohmann, V., Schwa¨rzle, V. &
Bartenschlager, R. (2003). Hepatitis C virus RNA replication is
resistant to tumor necrosis factor-a. J Gen Virol 84, 1253–1259.
Hellen, C. U. & Sarnow, P. (2001). Internal ribosome entry sites in
eukaryotic mRNA molecules. Genes Dev 15, 1593–1612.
Iwasaki, Y., Ikeda, H., Araki, Y., Osawa, T., Kita, K., Ando, M., Shimoe,
T., Takaguchi, K., Hashimoto, N. & other authors (2006). Limitation
of combination therapy of interferon and ribavirin for older patients
with chronic hepatitis C. Hepatology 43, 54–63.
Kanda, T., Steele, R., Ray, R. & Ray, B. R. (2007). Small interfering
RNA targeted to hepatitis C virus 59 nontranslated region exerts
potent antiviral effect. J Virol 81, 669–676.
Kapadia, S. B., Brideau-Andersen, A. & Chisari, F. V. (2003).
Interference of hepatitis C virus RNA replication by short interfering
RNAs. Proc Natl Acad Sci U S A 100, 2014–2018.
Kronke, J., Kittler, R., Buchholz, F., Windish, M. P., Pietschmann, T.,
Bartenshclager, R. & Frese, M. (2004). Alternative approaches for
efficient inhibition of hepatitis C virus RNA replication by small
interfering RNAs. J Virol 78, 3436–3446.
Mondal, T., Ray, U., Manna, A. K., Gupta, R., Roy, S. & Das, S. (2008).
Structural determinant of human La protein critical for internal
initiation of translation of hepatitis C virus RNA. J Virol 82, 11927–
11938.
Nijhara, R., Jana, S. S., Goswami, S. K., Rana, A., Majumdar, S. S.,
Kumar, V. & Sarkar, D. P. (2001). Sustained activation of mitogen-
activated protein kinases and activator protein 1 by the hepatitis B
virus X protein in mouse hepatocytes in vivo. J Virol 75, 10348–10358.
Pawlotsky, J. M., Chevaliez, S. & McHutchison, J. G. (2007). The
hepatitis C virus life cycle as a target for new antiviral therapies.
Gastroenterology 132, 1979–1998.
Pudi, R., Abhiman, S., Srinivasan, N. & Das, S. (2003). Hepatitis C
virus internal ribosome entry site-mediated translation is stimulated
by specific interaction of independent regions of human La
autoantigen. J Biol Chem 278, 12231–12240.
Pudi, R., Srinivasan, P. & Das, S. (2004). La protein binding at the
GCAC site near the initiator AUG facilitates the ribosomal assembly
on the hepatitis C virus RNA to influence internal ribosome entry
site-mediated translation. J Biol Chem 279, 29879–29888.
Pudi, R., Sudhamoni, S. R. & Das, S. (2005). A peptide derived from
RRM2 of human La protein binds to hepatitis C virus IRES, prevents
ribosomal assembly and inhibits internal initiation of translation.
J Virol 79, 9842–9853.
Ramani, K., Hassan, M. Q., Venkaiah, B., Hasnain, S. E. & Sarkar, D.
P. (1998). Site-specific gene delivery in vivo through engineered
Sendai viral envelopes. Proc Natl Acad Sci U S A 95, 11886–11890.
Randall, G., Grakoui, A. & Rice, C. M. (2003). Clearance of replicating
hepatitis C virus replicon RNAs in cell culture by small interfering
RNAs. Proc Natl Acad Sci U S A 100, 235–240.
Roy, S., Gupta, N., Subramanian, N., Mondal, T., Banerjea, A. C. &
Das, S. (2008). Sequence specific cleavage of hepatitis C virus RNA by
DNAzymes: inhibition of viral RNA translation and replication. J Gen
Virol 89, 1579–1586.
Saito, I., Miyamura, A., Ohbayashi, H., Harada, H., Katayama, T.,
Kikuchi, S., Watanabe, Y., Koi, S., Onji, M. & other authors (1990).
Hepatitis C virus infection is associated with the development of
hepatocellular carcinoma. Proc Natl Acad Sci U S A 87, 6547–6549.
Tan, S.-L., Pause, A., Shi, Y. & Sonenberg, N. (2002). Hepatitis C
therapeutics: current status and emerging strategies. Nat Rev Drug
Discov 1, 867–881.
Trepanier, J. B., Tanner, J. E. & Alfieri, C. (2006). Oligonucleotide-
based therapeutic options against hepatitis C virus infection. Antivir
Ther 11, 273–287.
Trowbridge, R. & Gowans, E. J. (1998). Identification of novel
sequences at the 59 terminus of the hepatitis C virus genome. J Viral
Hepat 5, 95–98.
Wang, C., Sarnow, P. & Siddiqui, A. (1993). Translation of human
hepatitis C virus RNA in cultured cells is mediated by an internal
ribosome-binding mechanism. J Virol 67, 3338–3344.
Wang, Q., Contag, H. C., Ilves, H., Johnston, H. B. & Kaspar, L. R.
(2005). Small hairpin RNAs efficiently inhibit hepatitis C IRES-
mediated gene expression in human tissue culture cells and a mouse
model. Mol Ther 12, 562–568.
Wilson, J. A., Jayasena, S., Khvorova, A., Sabatinos, S., Rodrigue-
Gervais, I., Arya, S., Sarangi, F., Harris-Brandts, M., Beaulieu, S. &
Richardson, C. D. (2003). RNA interference blocks gene expression
and RNA synthesis from hepatitis C replicons propagated in human
liver cells. Proc Natl Acad Sci U S A 100, 2783–2788.
Yi, M., Ma, Y., Yates, J. & Lemon, S. M. (2006).Compensatory mutations
in E1, p7, NS2 and NS3 enhance yields of cell culture-infectious inter-
genotypic chimeric hepatitis C virus. J Virol 81, 629–638.
Zhang, J., Yamada, O., Sakamoto, T., Yoshida, H., Iwai, T.,
Matsushita, Y., Shimamura, H., Araki, H. & Shimotohno, K. (2004).
Down-regualtion of viral relocation by adenoviral-mediated expres-
sion of siRNA against cellular cofactors for hepatitis C virus. Virology
320, 135–143.
shRNA targeting HCV RNA
http://vir.sgmjournals.org 1819
